These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31935484)

  • 1. 21
    Sauer UG; Barter RA; Becker RA; Benfenati E; Berggren E; Hubesch B; Hollnagel HM; Inawaka K; Keene AM; Mayer P; Plotzke K; Skoglund R; Albert O
    Regul Toxicol Pharmacol; 2020 Mar; 111():104583. PubMed ID: 31935484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerating the Pace of Chemical Risk Assessment.
    Kavlock RJ; Bahadori T; Barton-Maclaren TS; Gwinn MR; Rasenberg M; Thomas RS
    Chem Res Toxicol; 2018 May; 31(5):287-290. PubMed ID: 29600706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAM-supported read-across: From case studies to regulatory guidance in safety assessment.
    Rovida C; Escher SE; Herzler M; Bennekou SH; Kamp H; Kroese DE; Maslankiewicz L; Moné MJ; Patlewicz G; Sipes N; Van Aerts L; White A; Yamada T; Van de Water B
    ALTEX; 2021; 38(1):140-150. PubMed ID: 33452529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of substances with a carcinogenic potential in spray-formulated engine/brake cleaners and lubricating products, available in the European Union (EU) - based on IARC and EU-harmonised classifications and QSAR predictions.
    Sørli JB; Frederiksen M; Nikolov NG; Wedebye EB; Hadrup N
    Toxicology; 2022 Jul; 477():153261. PubMed ID: 35863487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grouping of UVCB substances with new approach methodologies (NAMs) data.
    House JS; Grimm FA; Klaren WD; Dalzell A; Kuchi S; Zhang SD; Lenz K; Boogaard PJ; Ketelslegers HB; Gant TW; Wright FA; Rusyn I
    ALTEX; 2021; 38(1):123-137. PubMed ID: 33086383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Frontier of Environmental Unknowns: Substances of Unknown or Variable Composition, Complex Reaction Products, or Biological Materials (UVCBs).
    Lai A; Clark AM; Escher BI; Fernandez M; McEwen LR; Tian Z; Wang Z; Schymanski EL
    Environ Sci Technol; 2022 Jun; 56(12):7448-7466. PubMed ID: 35533312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of New Approach Methodologies (NAMs) in regulatory decisions for chemical safety: Report from an EPAA Deep Dive Workshop.
    Westmoreland C; Bender HJ; Doe JE; Jacobs MN; Kass GEN; Madia F; Mahony C; Manou I; Maxwell G; Prieto P; Roggeband R; Sobanski T; Schütte K; Worth AP; Zvonar Z; Cronin MTD
    Regul Toxicol Pharmacol; 2022 Nov; 135():105261. PubMed ID: 36103951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches and considerations for the assessment of immunotoxicity for environmental chemicals: a workshop summary.
    Boverhof DR; Ladics G; Luebke B; Botham J; Corsini E; Evans E; Germolec D; Holsapple M; Loveless SE; Lu H; van der Laan JW; White KL; Yang Y
    Regul Toxicol Pharmacol; 2014 Feb; 68(1):96-107. PubMed ID: 24280359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The chemical landscape of high-throughput new approach methodologies for exposure.
    Isaacs KK; Egeghy P; Dionisio KL; Phillips KA; Zidek A; Ring C; Sobus JR; Ulrich EM; Wetmore BA; Williams AJ; Wambaugh JF
    J Expo Sci Environ Epidemiol; 2022 Nov; 32(6):820-832. PubMed ID: 36435938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the Environmental Risk Assessment of Substances of Unknown or Variable Composition, Complex Reaction Products, or Biological Materials.
    Salvito D; Fernandez M; Jenner K; Lyon DY; de Knecht J; Mayer P; MacLeod M; Eisenreich K; Leonards P; Cesnaitis R; León-Paumen M; Embry M; Déglin SE
    Environ Toxicol Chem; 2020 Nov; 39(11):2097-2108. PubMed ID: 32780492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).
    Tollefsen KE; Scholz S; Cronin MT; Edwards SW; de Knecht J; Crofton K; Garcia-Reyero N; Hartung T; Worth A; Patlewicz G
    Regul Toxicol Pharmacol; 2014 Dec; 70(3):629-40. PubMed ID: 25261300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk assessment of 'endocrine substances': guidance on identifying endocrine disruptors.
    Lewis RW
    Toxicol Lett; 2013 Dec; 223(3):287-90. PubMed ID: 24036001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes.
    Patlewicz G; Simon TW; Rowlands JC; Budinsky RA; Becker RA
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):463-77. PubMed ID: 25707856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathway-based toxicity: history, current approaches and liver fibrosis and steatosis as prototypes.
    Willett C; Caverly Rae J; Goyak KO; Landesmann B; Minsavage G; Westmoreland C
    ALTEX; 2014; 31(4):407-21. PubMed ID: 24954301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing context appropriate toxicity testing approaches using new alternative methods (NAMs).
    Andersen ME; McMullen PD; Phillips MB; Yoon M; Pendse SN; Clewell HJ; Hartman JK; Moreau M; Becker RA; Clewell RA
    ALTEX; 2019; 36(4):523-534. PubMed ID: 31664457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays.
    House JS; Grimm FA; Klaren WD; Dalzell A; Kuchi S; Zhang SD; Lenz K; Boogaard PJ; Ketelslegers HB; Gant TW; Rusyn I; Wright FA
    ALTEX; 2022; 39(3):388–404. PubMed ID: 35288757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New ideas for non-animal approaches to predict repeated-dose systemic toxicity: Report from an EPAA Blue Sky Workshop.
    Mahony C; Ashton RS; Birk B; Boobis AR; Cull T; Daston GP; Ewart L; Knudsen TB; Manou I; Maurer-Stroh S; Margiotta-Casaluci L; Müller BP; Nordlund P; Roberts RA; Steger-Hartmann T; Vandenbossche E; Viant MR; Vinken M; Whelan M; Zvonimir Z; Cronin MTD
    Regul Toxicol Pharmacol; 2020 Jul; 114():104668. PubMed ID: 32335207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment in the 21st century: where are we heading?
    Brescia S; Alexander-White C; Li H; Cayley A
    Toxicol Res (Camb); 2023 Feb; 12(1):1-11. PubMed ID: 36866215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.